Home › Funds › Rangeley Capital, LLC › KROS

Rangeley Capital, LLC position in KROS

KEROS THERAPEUTICS INC · Health Care

Rangeley Capital, LLC reported holding 54,400 shares of KROS (KEROS THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$582K, representing 0.55% of its reported portfolio and ranking #47 among its reported holdings. Rangeley Capital, LLC has disclosed KROS holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)54.40K sh
Reported value held$582.08K
Portfolio Weight0.55%
First reportedQ1 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Rangeley Capital, LLC's KROS position evolved

Rangeley Capital, LLC first disclosed a stake in KROS in Q1 2025 at 408,234 shares (US$4.2M). Across 6 filings, Rangeley Capital, LLC increased the stake 0 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 54,400 shares valued at US$582K. Notable position changes include a 30% trim in Q2 2025 (shares rose 19% over the following quarter), a 63% trim in Q4 2025 (shares fell 46% over the following quarter), a 44% trim in Q1 2026 (shares fell 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 408.23K $4.16M New
Q2 2025 285.40K $3.81M Reduce
Q3 2025 258.62K $4.09M Reduce
Q4 2025 96.80K $1.97M Reduce
Q1 2026 54.40K $600.58K Reduce
Q2 2026 54.40K $582.08K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KROS and 13F data

KROS (KEROS THERAPEUTICS INC) is a Health Care company. 13 other funds we track also report a position in KROS — the largest reported positions include Nantahala Capital Management, LLC (US$15.1M), Madison Avenue Partners, LP (US$6.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KROS

All KROS fund holders →

FAQ

How long has Rangeley Capital, LLC held KROS?

Rangeley Capital, LLC has disclosed KROS holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

What is Rangeley Capital, LLC's current position in KROS?

As of Q2 2026, Rangeley Capital, LLC holds 54.40K shares of KROS (KEROS THERAPEUTICS INC), valued at $582.08K, representing 0.55% of its reported portfolio and ranking #47.

Has Rangeley Capital, LLC been buying or selling KROS?

In the latest 13F filing (Q2 2026), Rangeley Capital, LLC held unchanged its position in KROS.

Which other funds hold KROS?

Other major institutional holders of KROS include Nantahala Capital Management, LLC, Madison Avenue Partners, LP, among 13 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.